Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer

<p>Abstract</p> <p>Background</p> <p>Real-time quantitative PCR (RQ-PCR) forms the basis of many breast cancer biomarker studies and novel prognostic assays, paving the way towards personalised cancer treatments. Normalisation of relative RQ-PCR data is required to control for non-biological variation introduced during sample preparation. Endogenous control (EC) genes, used in this context, should ideally be expressed constitutively and uniformly across treatments in all test samples. Despite widespread recognition that the accuracy of the normalised data is largely dependent on the reliability of the EC, there are no reports of the systematic validation of genes commonly used for this purpose in the analysis of gene expression by RQ-PCR in primary breast cancer tissues. The aim of this study was to identify the most suitable endogenous control genes for RQ-PCR analysis of primary breast tissue from a panel of eleven candidates in current use. Oestrogen receptor alpha (<it>ESR1</it>) was used a target gene to compare the effect of choice of EC on the estimate of gene quantity.</p> <p>Results</p> <p>The expression and validity of candidate ECs (<it>GAPDH</it>, <it>TFRC</it>, <it>ABL</it>, <it>PPIA</it>, <it>HPRT1</it>, <it>RPLP0</it>, <it>B2M</it>, <it>GUSB</it>, <it>MRPL19</it>, <it>PUM1 </it>and <it>PSMC4) </it>was determined in 6 benign and 21 malignant primary breast cancer tissues. Gene expression data was analysed using two different statistical models. <it>MRPL19 </it>and <it>PPIA </it>were identified as the most stable and reliable EC genes, while <it>GUSB</it>, <it>RPLP0 </it>and <it>ABL </it>were least stable. There was a highly significant difference in variance between ECs. <it>ESR1 </it>expression was appreciably higher in malignant compared to benign tissues and there was a significant effect of EC on the magnitude of the error associated with the relative quantity of <it>ESR1</it>.</p> <p>Conclusion</p> <p>We have validated two endogenous control genes, <it>MRPL19</it> and <it>PPIA</it>, for RQ-PCR analysis of gene expression in primary breast tissue. Of the genes in current use in this field, the above combination offers increased accuracy and resolution in the quantitation of gene expression data, facilitating the detection of smaller changes in gene expression than otherwise possible. The combination identified here is a good candidate for use as a two-gene endogenous control in a broad spectrum of future research and diagnostic applications in breast cancer.</p

MicroRNAs as Novel Biomarkers for Breast Cancer

Breast cancer is a complex phenotypically diverse genetic disease, involving a variety of changes in gene expression and structure. Recent advances in molecular profiling technology have made great progress in unravelling the molecular taxonomy of breast cancer, which has shed new light on the aetiology of the disease and also heralded great potential for the development of novel biomarkers and therapeutic targets. Mi(cro)RNAs are a contemporary class of small noncoding endogenous RNA molecules, generating great excitement in the clinical and scientific communities. The recent discovery that miRNA expression is frequently dysregulated in cancer has uncovered an entirely new repertoire of molecular factors upstream of gene expression, which warrants extensive investigation to further elucidate their precise role in malignancy. We present a comprehensive and timely review of the role of miRNAs in cancer: addressing miRNA function, their putative role as oncogenes or tumor suppressors, with a particular emphasis on breast cancer throughout. We discuss the recent discovery of quantifiable circulating cancer-associated miRNAs, which heralds immense potential for their use as novel minimally invasive biomarkers for breast and other cancers. Finally, we comment on the potential role of miRNAs in breast cancer management, particularly in improving current prognostic tools and achieving the goal of individualized cancer treatment

Complementary and alternative medicine use in oncology: A questionnaire survey of patients and health care professionals

<p>Abstract</p> <p>Background</p> <p>We aimed to investigate the prevalence and predictors of Complementary and Alternative Medicine (CAM) use among cancer patients and non-cancer volunteers, and to assess the knowledge of and attitudes toward CAM use in oncology among health care professionals.</p> <p>Methods</p> <p>This is a cross-sectional questionnaire survey conducted in a single institution in Ireland. Survey was performed in outpatient and inpatient settings involving cancer patients and non-cancer volunteers. Clinicians and allied health care professionals were asked to complete a different questionnaire.</p> <p>Results</p> <p>In 676 participants including 219 cancer patients; 301 non-cancer volunteers and 156 health care professionals, the overall prevalence of CAM use was 32.5% (29.1%, 30.9% and 39.7% respectively in the three study cohorts). Female gender (p < 0.001), younger age (p = 0.004), higher educational background (p < 0.001), higher annual household income (p = 0.001), private health insurance (p = 0.001) and non-Christian (p < 0.001) were factors associated with more likely CAM use. Multivariate analysis identified female gender (p < 0.001), non-Christian (p = 0.001) and private health insurance (p = 0.015) as independent predictors of CAM use. Most health care professionals thought they did not have adequate knowledge (58.8%) nor were up to date with the best evidence (79.2%) on CAM use in oncology. Health care professionals who used CAM were more likely to recommend it to patients (p < 0.001).</p> <p>Conclusions</p> <p>This study demonstrates a similarly high prevalence of CAM use among oncology health care professionals, cancer and non cancer patients. Patients are more likely to disclose CAM usage if they are specifically asked. Health care professionals are interested to learn more about various CAM therapies and have poor evidence-based knowledge on specific oncology treatments. There is a need for further training to meet to the escalation of CAM use among patients and to raise awareness of potential benefits and risks associated with these therapies.</p

Malignant Phyllodes Tumour with Liposarcomatous Differentiation, Invasive Tubular Carcinoma, and Ductal and Lobular Carcinoma In Situ: Case Report and Review of the Literature

A 43-year-old woman presented with a right breast lump that had enlarged over 5 months. She had chemoradiotherapy for non-Hodgkin's lymphoma in 1989. Histology revealed a malignant phyllodes tumour (PT) with liposarcomatous differentiation and ductal carcinoma in situ (DCIS) within the tumour with invasive tubular carcinoma, DCIS, and lobular carcinoma in situ in the surrounding breast. She had surgery and adjuvant radiotherapy. One year follow-up showed no recurrence or metastatic disease. Liposarcomatous differentiation is uncommon in PTs, and coexisting carcinoma is rare with 38 cases in 31 reports in the literature. Carcinoma is reported in malignant (n = 19), benign (n = 16) and in borderline PTs (n = 3) with invasive carcinoma (n = 18) and pure in situ carcinoma (n = 19) recorded in equal frequency. Carcinoma is more commonly found within the confines of benign PTs; whereas it is more often found surrounding the PT or in the contralateral breast in malignant PTs. Previous radiotherapy treatment is reported in only two cases. The aetiology of co-existing carcinoma is unclear but the rarity of previous radiotherapy treatment suggests that it is incidental. This case highlights the diverse pathology that can occur with PTs, which should be considered when evaluating pathology specimens as they may impact on patient management

Fibrinogen and associated risk factors in a high-risk population: urban indigenous australians, the druid Study

<p>Abstract</p> <p>Background</p> <p>Epidemiological evidence suggests that fibrinogen and CRP are associated with coronary heart disease risk. High CRP in Indigenous Australians has been reported in previous studies including our 'Diabetes and Related diseases in Urban Indigenous population in Darwin region' (DRUID) Study. We studied levels of fibrinogen and its cross-sectional relationship with traditional and non-traditional cardiovascular risk factors in an urban Indigenous Australian cohort.</p> <p>Methods</p> <p>Fibrinogen data were available from 287 males and 628 females (aged ≥ 15 years) from the DRUID study. Analysis was performed for associations with the following risk factors: diabetes, HbA1c, age, BMI, waist circumference, waist-hip ratio, total cholesterol, triglyceride, HDL cholesterol, C-reactive protein, homocysteine, blood pressure, heart rate, urine ACR, smoking status, alcohol abstinence.</p> <p>Results</p> <p>Fibrinogen generally increased with age in both genders; levels by age group were higher than those previously reported in other populations, including Native Americans. Fibrinogen was higher in those with than without diabetes (4.24 vs 3.56 g/L, p < 0.001). After adjusting for age and sex, the following were significantly associated with fibrinogen: BMI, waist, waist-hip ratio, systolic blood pressure, heart rate, fasting triglycerides, HDL cholesterol, HbA1c, CRP, ACR and alcohol abstinence. On multivariate regression (age and sex-adjusted) CRP and HbA1c were significant independent predictors of fibrinogen, explaining 27% of its variance; CRP alone explained 25% of fibrinogen variance. On factor analysis, both CRP and fibrinogen clustered with obesity in women (this factor explained 20% of variance); but in men, CRP clustered with obesity (factor explained 18% of variance) whilst fibrinogen clustered with HbA1c and urine ACR (factor explained 13% of variance).</p> <p>Conclusions</p> <p>Fibrinogen is associated with traditional and non-traditional cardiovascular risk factors in this urban Indigenous cohort and may be a useful biomarker of CVD in this high-risk population. The apparent different associations of fibrinogen with cardiovascular disease risk markers in men and women should be explored further.</p

Serum vitamin D levels, diabetes and cardio-metabolic risk factors in Aboriginal and Torres Strait Islander Australians

Assesses levels of serum 25(OH)D in Aboriginal and Torres Strait Islander Australians and explores relationships between 25(OH)D and cardio-metabolic risk factors and diabetes. Abstract Background: Low levels of serum 25 – hydroxy vitamin D (25(OH)D), have been associated with development of type 2 diabetes and cardiovascular disease (CVD); however there are limited data on serum 25(OH)D in Indigenous Australians, a population at high risk for both diabetes and CVD. We aimed to assess levels of serum 25(OH)D in Aboriginal and Torres Strait Islander Australians and to explore relationships between 25(OH)D and cardio-metabolic risk factors and diabetes. Methods: 592 Aboriginal and/or Torres Strait Islander Australian participants of The eGFR (estimated glomerular filtration rate) Study, a cross-sectional analysis of a cohort study performed in 2007 – 2011, from urban and remote centres within communities, primary care and tertiary hospitals across Northern Territory, Far North Queensland and Western Australia. Assessment of serum 25(OH)D, cardio-metabolic risk factors (central obesity, diabetes, hypertension, history of cardiovascular disease, current smoker, low HDL-cholesterol), and diabetes (by history or HbA1c ≥ 6.5%) was performed. Associations were explored between 25(OH)D and outcome measures of diabetes and number of cardio-metabolic risk factors. Results: The median (IQR) serum 25(OH)D was 60 (45 – 77) nmol/L, 31% had 25(OH)D &lt;50 nmol/L. For participants with 25(OH)D &lt; 50 vs ≥ 50 nmol/L, cardio-metabolic risk profile differed for: diabetes (54%, 36% p &lt; 0.001), past history of cardiovascular disease (16%, 9%, p = 0.014), waist-hip ratio (0.98, 0.92, p &lt; 0.001), urine albumin-creatinine ratio (2.7, 1.5 mg/mmol, p &lt; 0.001). The OR (95% CI) for diabetes was 2.02 (1.03 – 3.95) for people in the lowest vs highest tertiles of 25(OH)D (&lt;53 vs &gt;72 nmol/L, respectively) after adjusting for known cardio-metabolic risk factors. Conclusion: The percentage of 25(OH)D levels &lt;50 nmol/L was high among Aboriginal and Torres Strait Islander Australians from Northern and Central Australia. Low 25(OH)D level was associated with adverse cardio-metabolic risk profile and was independently associated with diabetes. These findings require exploration in longitudinal studies

Advances in mesenchymal stem cell-mediated gene therapy for cancer

Mesenchymal stem cells have a natural tropism for tumours and their metastases, and are also considered immunoprivileged. This remarkable combination of properties has formed the basis for many studies investigating their potential as tumour-specific delivery vehicles for suicide genes, oncolytic viruses and secreted therapeutic proteins. The aim of the present review is to discuss the range of approaches that have been used to exploit the tumour-homing capacity of mesenchymal stem cells for gene delivery, and to highlight advances required to realize the full potential of this promising approach

Revision of the Eocene \u27Platyrhina\u27 species from the Bolca Lagerstätte (Italy) reveals the first panray (Batomorphii: Zanobatidae) in the fossil record

The fossil-Lagerstätte of Bolca (Italy) is well known for the diversity and exquisite preservation of its bony and cartilaginous fishes documenting tropical shallow-water marine environments associated with coral reefs in the western Tethys during the early Eocene. In this study, the taxonomic, systematic and phylogenetic position of two batoid species traditionally assigned to the living thornback ray genus Platyrhina is re-evaluated. †Platyrhina bolcensis Heckel, 1851 is recognized as a separate species of the Platyrhinidae because of its plate-like antorbital cartilage with an irregular outline and a small horn on the nasal capsules. Also, the rostral cartilage does not reach the anterior border of the disc. Support for the placement of this species within the new genus †Eoplatyrhina gen. nov. is based on a combination of morphological and meristic features (e.g. nasal capsules at right angles to the rostrum; large space between the hyomandibulae and mandibular arch; approximately 132 vertebral centra; 15–16 rib pairs; 81–87 pectoral radials; 18–21 pelvic radials; short, straight and stout claspers; 40–50 caudal-fin radials; thorns absent). A second species, †Platyrhina egertoni (De Zigno, 1876), is more closely related to the living panray Zanobatus than Platyrhina and is assigned here to †Plesiozanobatus gen. nov. because of a combination of characters that support its placement within the family Zanobatidae (tail stout and short, distinctly demarcated from disc; two dorsal fins and complete caudal fin; small dermal denticles and scattered thorns covering disc and tail; rostral cartilage absent; nasal capsules without horn-like processes; mesopterygium absent). The systematic position of a third taxon, †Platyrhina gigantea (Blainville, 1818), is currently impossible to establish due to the poor preservation of the only known specimen, and therefore we propose to consider it a nomen dubium. Palaeoecological and biogeographic features of the Eocene platyrhinids and zanobatids from Bolca are also discussed

Mentoring in students' adaptation to labor market requirements

The article contains the analyzes of the problems of youth employment, the development of mentoring in Russia. The ways of their joint decision are proposed with the purpose of acquiring production experience, professional self-realization and increasing the competitiveness of future specialists